Skip to Main Content
Table 1

Correlation of PSMAa expression status with clinical parameters and disease outcome in 136 cases of prostate cancer treated by radical prostatectomy

Clinical parameter/disease outcomePSMA expression status (no. of patients)Significance (P)
Nonoverexpressingb (71)Overexpressingc (65)
Mean preoperative PSA (ng/ml) 9.10 ± 5.91 18.28 ± 17.70 0.006 
Mean tumor Gleason score 5.92 ± 1.20 6.33 ± 1.21 0.04 
Mean DNA index (diploid = 1.00) 1.03 ± 0.33 1.32 ± 0.50 0.002 
Advanced tumor stage (III/IV) 23/71 (32%) 33/65 (51%) 0.029 
Recurrent disease 20/71 (28%) 37/65 (57%) 0.001 
Mean time to recurrence (mo) 43.75 34.78 0.001 
Clinical parameter/disease outcomePSMA expression status (no. of patients)Significance (P)
Nonoverexpressingb (71)Overexpressingc (65)
Mean preoperative PSA (ng/ml) 9.10 ± 5.91 18.28 ± 17.70 0.006 
Mean tumor Gleason score 5.92 ± 1.20 6.33 ± 1.21 0.04 
Mean DNA index (diploid = 1.00) 1.03 ± 0.33 1.32 ± 0.50 0.002 
Advanced tumor stage (III/IV) 23/71 (32%) 33/65 (51%) 0.029 
Recurrent disease 20/71 (28%) 37/65 (57%) 0.001 
Mean time to recurrence (mo) 43.75 34.78 0.001 
a

PSMA, prostate-specific membrane antigen; PSA, prostate-specific antigen.

b

Low staining intensity.

c

High staining intensity.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept